GU Oncology Clinical Trials

Infinity IPI-549-02

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Learn more.


NRG-GU005

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

Learn more.


NRG-GU002

Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel

Learn more.


NRG-GU006

A Phase II, Double-blinded, Placebo-controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide In Recurrent Prostate Cancer

Learn more.


EA8153

Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel

Learn more.


A031501

Phase III Randomized Adjuvant study of MK3475 (Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma versus Observation

Learn more.


EA8143

A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Learn more.


Merck-3475-905

A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-905)

Learn more.


Merck-3475-866

A Phase 3 Trial of Peri-operative Pembrolizumab + Neoadjuvant Chemotherapy vs. Placebo + Neoadjuvant Chemotherapy for Cis-Eligible MIBC

Learn more.